Pancreatic Cancer Research

ResearcherUniversity of MichiganNo recent work listed

Yaqing Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-6019-0844; OpenAlex author ID A5115593514. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 5 papers · 2022: 3 papers · 2023: 2 papers

Papers 21

  1. Tyrosine Sulfation: A New Player and Potential Target in Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2023.06.007↗
  2. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  3. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  4. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  5. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway. Co-author DOI 10.7554/elife.73796↗
  6. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. Co-author DOI 10.1016/j.jcmgh.2020.08.011↗
  7. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Co-author DOI 10.1158/0008-5472.can-20-3929↗
  8. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  9. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  10. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.682217↗
  11. Discoidin Domain Receptor 1 (DDR1) Is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2020.03.020↗
  12. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  13. Epithelial-Stromal Interactions in Pancreatic Cancer. Co-author DOI 10.1146/annurev-physiol-020518-114515↗
  14. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312078↗
  15. Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Co-author DOI 10.1093/carcin/bgv058↗
  16. CD44 regulates pancreatic cancer invasion through MT1-MMP. First author DOI 10.1158/1541-7786.mcr-14-0076↗
  17. Dosage-dependent regulation of pancreatic cancer growth and angiogenesis by hedgehog signaling. First author DOI 10.1016/j.celrep.2014.09.010↗
  18. Immune cells in pancreatic cancer: Joining the dark side. Co-author DOI 10.4161/onci.29125↗
  19. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Co-author DOI 10.1158/0008-5472.can-13-1558-t↗
  20. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. Co-author DOI 10.1172/jci59227↗
  21. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. Co-author DOI 10.1371/journal.pone.0049707↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 21 shared papers, 2012–2023 · strength 2.23
  2. Howard C. Crawford · 10 shared papers, 2019–2023 · strength 1.11
  3. Nina G. Steele · 7 shared papers, 2021–2022 · strength 0.76
  4. Costas Andreas Lyssiotis · 7 shared papers, 2019–2023 · strength 0.73
  5. Filip Bednar · 9 shared papers, 2012–2023 · strength 0.69
  6. Zeribe C. Nwosu · 6 shared papers, 2021–2023 · strength 0.65
  7. Samantha B. Kemp · 6 shared papers, 2019–2022 · strength 0.57
  8. Christopher J. Halbrook · 5 shared papers, 2019–2023 · strength 0.53
  9. Eileen S. Carpenter · 4 shared papers, 2021–2023 · strength 0.42
  10. Daniel James Salas-Escabillas · 3 shared papers, 2021–2023 · strength 0.38
  11. Rosa Elena Menjivar · 3 shared papers, 2021–2023 · strength 0.37
  12. Wenting Du · 2 shared papers, 2021–2023 · strength 0.36
  13. Katelyn L. Donahue · 3 shared papers, 2021–2023 · strength 0.34
  14. Li Zhang · 3 shared papers, 2019–2022 · strength 0.31
  15. Megan T. Hoffman · 3 shared papers, 2021–2022 · strength 0.30
  16. Benjamin Allen · 3 shared papers, 2014–2022 · strength 0.26
  17. Timothy L. Frankel · 3 shared papers, 2019–2021 · strength 0.25
  18. Meredith A. Collins · 5 shared papers, 2012–2015 · strength 0.19
  19. Kenneth P. Olive · 2 shared papers, 2015–2022 · strength 0.16
  20. Diane M. Simeone · 3 shared papers, 2015–2017 · strength 0.16
  21. Padma Kadiyala · 1 shared paper, 2023 · strength 0.14
  22. Allison Bischoff · 1 shared paper, 2023 · strength 0.14
  23. Seth Boyer · 1 shared paper, 2022 · strength 0.13
  24. Matthew H. Ward · 1 shared paper, 2022 · strength 0.13
  25. Rima Singh · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.